keyword
MENU ▼
Read by QxMD icon Read
search

angiotensin 1-7

keyword
https://www.readbyqxmd.com/read/29783197/quantification-of-21-antihypertensive-drugs-in-serum-using-uhplc-ms-ms
#1
Per Ole M Gundersen, Arne Helland, Olav Spigset, Solfrid Hegstad
BACKGROUND: Poor drug adherence in hypertensive patients can lead to treatment failure and increased cardiovascular morbidity, as well as increased costs to society. An analytical method based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MSMS) was developed and validated for use in routine therapeutic drug monitoring (TDM). The method includes 21 antihypertensive drugs or active metabolites from the groups beta blockers (n=5), calcium antagonists (n=5), angiotensin II receptor antagonists (n=4), angiotensin converting enzyme (ACE) inhibitors (n=3) and diuretics (n = 3), in addition to one α1-selective alpha blocker...
April 28, 2018: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29782633/macrothrombocytopenia-renal-dysfunction-and-nephrotic-syndrome-in-a-young-male-patient-a-case-report-of-myh9-related-disease
#2
Gabriela Sevignani, Giovana Memari Pavanelli, Sibele Sauzem Milano, Bianca Ramos Ferronato, Maria Aparecida Pachaly, Hae Ii Cheong, Mauricio de Carvalho, Fellype Carvalho Barreto
MYH9-related disease is an autosomal dominant disorder caused by mutations of the MYH9 gene, which encodes the non-muscle myosin heavy chain IIA on chromosome 22q12. It is characterized by congenital macrothrombocytopenia, bleeding tendency, hearing loss, and cataracts. Nephropathy occurs in approximately 30% of MYH9-related disease in a male patient carrier of a de novo missense mutation in exon 1 of the MYH9 gene [c.287C > T; p.Ser(TCG)96(TTG)Leu]. He presented all phenotypic manifestations of the disease, but cataracts...
May 17, 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29774407/beta-blockers-and-chronic-heart-failure-patients-prognostic-impact-of-a-dose-targeted-beta-blocker-therapy-vs-heart-rate-targeted-strategy
#3
Anna Corletto, Hanna Fröhlich, Tobias Täger, Matthias Hochadel, Ralf Zahn, Caroline Kilkowski, Ralph Winkler, Jochen Senges, Hugo A Katus, Lutz Frankenstein
BACKGROUND: Beta blockers improve survival in patients with chronic systolic heart failure (CHF). Whether physicians should aim for target dose, target heart rate (HR), or both is still under debate. METHODS AND RESULTS: We identified 1,669 patients with systolic CHF due to ischemic heart disease or idiopathic dilated cardiomyopathy from the University Hospital Heidelberg and the Clinic of Ludwigshafen, Germany. All patients were treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker and had a history of CHF known for at least 6 months...
May 17, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29768290/intense-aerobic-exercise-lowers-blood-pressure-in-individuals-with-metabolic-syndrome-taking-antihypertensive-medicine
#4
Miguel Ramirez-Jimenez, Valentin Fernandez-Elias, Felix Morales-Palomo, Juan F Ortega, Ricardo Mora-Rodriguez
OBJECTIVE: There is a growing tendency for physicians to prescribe exercise in accordance with the 'exercise is medicine' global health initiative. However, the exercise-pharmacologic interactions for controlling blood pressure are not well described. Our purpose was to study whether angiotensin II receptor type 1 blocker (ARB) antihypertensive medicine enhances the blood pressure-lowering effects of intense exercise. PARTICIPANTS AND METHODS: Fifteen hypertensive individuals with metabolic syndrome chronically medicated with ARB underwent two exercise trials in a blind randomized order...
May 15, 2018: Blood Pressure Monitoring
https://www.readbyqxmd.com/read/29761600/loss-of-angiotensin-converting-enzyme-2-exacerbates-diabetic-retinopathy-by-promoting-bone-marrow-dysfunction
#5
Yaqian Duan, Eleni Beli, Sergio Li Calzi, Judith L Quigley, Rehae C Miller, Leni Moldovan, Dongni Feng, Tatiana E Salazar, Sugata Hazra, Jude Al-Sabah, Kakarla V Chalam, Thao Le Phuong Trinh, Marya Meroueh, Troy A Markel, Matthew C Murray, Ruchi J Vyas, Michael E Boulton, Patricia Parsons-Wingerter, Gavin Y Oudit, Alexander G Obukhov, Maria B Grant
Angiotensin-converting enzyme 2 (ACE2) is the primary enzyme of the vasoprotective axis of the renin angiotensin system (RAS). We tested the hypothesis that loss of ACE2 would exacerbate diabetic retinopathy by promoting bone marrow dysfunction. ACE2-/y were crossed with Akita mice, a model of type 1 diabetes. When comparing the bone marrow of the ACE2-/y -Akita mice to that of Akita mice, we observed a reduction of both short-term and long-term repopulating hematopoietic stem cells, a shift of hematopoiesis towards myelopoiesis, and an impairment of lineage- c-kit+ hematopoietic stem/progenitor cell (HS/PC) migration and proliferation...
May 15, 2018: Stem Cells
https://www.readbyqxmd.com/read/29752040/mesenchymal-stem-cell-derived-microvesicles-alleviate-pulmonary-arterial-hypertension-by-regulating-renin-angiotensin-system
#6
Zhenjun Liu, Jinghu Liu, Mengyuan Xiao, Junxian Wang, Feng Yao, Weikai Zeng, Liqin Yu, Yuejie Guan, Wenyan Wei, Zijian Peng, Kunpeng Zhu, Jin Wang, Zhongyuan Yang, Jixin Zhong, Jianying Chen
In recent years, microvesicles (MVs) derived from mesenchymal stem cells (MSCs) have been proved to be able to improve the outcome of pulmonary arterial hypertension (PAH) in many respects, but the underlying mechanisms of it still remain unclear. Because the renin-angiotensin system (RAS) has been found to be closely related to PAH, the present study was designed to investigate whether the effect of MSC-derived MVs on PAH was correlated with RAS. MVs were isolated and purified from bone marrow MSCs. PAH rat models were established by a single intraperitoneal injection of 1% monocrotaline (MCT, 50 mg/Kg)...
March 15, 2018: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/29749551/angiotensin-ii-inhibits-the-protein-expression-of-zo%C3%A2-1-in-vascular-endothelial-cells-by-downregulating-ve%C3%A2-cadherin
#7
Longbin Liu, Liping Meng, Peng Zhang, Hui Lin, Jufang Chi, Fang Peng, Hangyuan Guo
Angiotensin II (Ang II) is reported to be involved in the development of various cardiovascular diseases by disrupting microvessel permeability, however, the underlying mechanism remains to be elucidated. The present study aimed to investigate the mechanism by which Ang II disrupts microvascular permeability. Rat endothelial cells were subjected to primary culture and identification. Cells in passages 4‑7 were then used for the following experiments. The cells were divided into control, Ang II, and Ang II + valsartan groups, and reverse transcription‑quantitative polymerase chain reaction and western blot analyses were perform to evaluate the expression of zonula occludens‑1 (ZO‑1) and vascular endothelial (VE)‑cadherin in the cells...
May 8, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29749426/-corrigendum-protective-effect-of-angiotensin%C3%A2-1%C3%A2-7-against-hyperglycaemia%C3%A2-induced-injury-in-h9c2-cardiomyoblast-cells-via-the-pi3k%C3%AC-akt-signaling-pathway
#8
Yi-Ying Yang, Xiu-Ting Sun, Zheng-Xun Li, Wei-Yan Chen, Xiang Wang, Mei-Ling Liang, Hui Shi, Zhi-Sheng Yang, Wu-Tao Zeng
Subsequently to the publication of this article, the authors have realized that an address affiliation associated with certain of the authors had been omitted. The authors' affiliation information should have appeared as follows (the omitted address affiliation is featured in bold): Yi‑Ying Yang1,2*, Xiu‑Ting Sun1,2*, Zheng‑Xun Li1,2, Wei‑Yan Chen3, Xiang Wang4, Mei‑Ling Liang5, Hui Shi1,2, Zhi‑Sheng Yang1,2 and Wu‑Tao Zeng1,2 1Department of Cardiology, The First Affiliated Hospital, Sun Yat‑Sen University; 2Key Laboratory on Assisted Circulation, Ministry of Health, Guangzhou, Guangdong 510080; 3Intensive Care Unit, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260; 4Department of Cardiology, Laiwu City People's Hospital, Laiwu, Shandong 27110; 5Department of Cardiology, Sun Yat‑Sen Cardiovascular Hospital, Shenzhen, Guangdong 518020, P...
May 7, 2018: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29748913/efficacy-and-tolerability-of-fixed-dose-combination-perindopril-indapamide-in-hypertensive-patients-with-a-history-of-stroke-or-transient-ischemic-attack-picasso-trial
#9
Csaba András Dézsi, Csaba Farsang
INTRODUCTION: In everyday medical practice, physicians often need to manage patients whose blood pressure is not well controlled. Those with a history of cerebrovascular disease are a high-risk group in need of rapid blood pressure control. METHODS: The PICASSO study was a real-life, observational trial involving 9257 inadequately treated hypertensive patients who were switched from previous therapy to the fixed-dose combination of perindopril 10 mg/indapamide 2...
May 10, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29741224/angiotensin-ii-enhances-the-acetylation-and-release-of-hmgb1-in-raw264-7-macrophage
#10
Shanshan Zhou, Hongxiang Lu, Rong Chen, Yu Tian, YuanYuan Jiang, Shiqing Zhang, Daobing Ni, Zhaoliang Su, Xiaoyi Shao
The high-mobility group box-1 (HMGB1), as a highly conserved ubiquitous DNA-binding protein, has been widely studied in various diseases, including inflammation and tumor; however, fewer studies were focused on the mechanisms controlling HMGB1 release compared with the function of HMGB1. Previous studies have proven that ANG II can act as a pro-inflammatory cytokine, both of HMGB1 and ANG II were significantly upregulated in autoimmune diseases, however, the exact role of ANG II in regulating HMGB1 release have not been shown...
May 9, 2018: Cell Biology International
https://www.readbyqxmd.com/read/29733881/cognitive-benefits-of-angiotensin-iv-and-angiotensin-1-7-a-systematic-review-of-experimental-studies
#11
REVIEW
Jean K Ho, Daniel A Nation
OBJECTIVES: To explore effects of the brain renin-angiotensin system (RAS) on cognition. DESIGN: Systematic review of experimental (non-human) studies assessing cognitive effects of RAS peptides angiotensin-(3-8) [Ang IV] and angiotensin-(1-7) [Ang-(1-7)] and their receptors, the Ang IV receptor (AT4R) and the Mas receptor. RESULTS: Of 450 articles identified, 32 met inclusion criteria. Seven of 11 studies of normal animals found Ang IV had beneficial effects on tests of passive or conditioned avoidance and object recognition...
May 4, 2018: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/29731121/sudden-death-after-hospitalization-for-heart-failure-with-reduced-ejection-fraction-from-the-everest-trial
#12
Muthiah Vaduganathan, Ravi B Patel, Robert J Mentz, Haris Subacius, Neal A Chatterjee, Stephen J Greene, Andrew P Ambrosy, Aldo P Maggioni, James E Udelson, Karl Swedberg, Marvin A Konstam, Christopher M O'Connor, Javed Butler, Mihai Gheorghiade, Faiez Zannad
Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD). Contemporary estimates of SCD risk after hospitalization for heart failure are limited. We describe the incidence, timing, and clinical predictors of SCD after hospitalization for HFrEF (≤40%) in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial. Multiple logistic regression analyses tested >30 baseline covariates (including treatment randomization, demographics, comorbid conditions, natriuretic peptides, ejection fraction, and medical and device therapies) to identify predictors of 1-year SCD...
April 11, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29731118/post-traumatic-stress-disorder-and-heart-failure-in-men-within-the-veteran-affairs-health-system
#13
Marat Fudim, Lukasz P Cerbin, Srikant Devaraj, Tarek Ajam, Sunil V Rao, Masoor Kamalesh
Patients with post-traumatic stress disorder (PTSD) are at risk of multiple co-morbidities and are more likely to develop incident heart failure with reduced ejection fraction (HFrEF). The relation of PTSD with clinical outcomes in HFrEF is not established. US veterans diagnosed with HFrEF from January 2007 to January 2015 and treated nationwide in the Veterans Affairs (VA) Health System were included in the study. Patients with HFrEF were identified through International Classification of Diseases, Ninth Revision (ICD-9) codes...
April 11, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29728119/epidemiology-of-bradykinin-mediated-angioedema-a-systematic-investigation-of-epidemiological-studies
#14
Emel Aygören-Pürsün, Markus Magerl, Andreas Maetzel, Marcus Maurer
BACKGROUND: Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management. METHODS: We systematically searched the medical literature to identify abstracts of interest indexed between 1948 and March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany and France...
May 4, 2018: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/29725433/cinobufacini-promotes-apoptosis-of-bladder-cancer-cells-by-influencing-the-expression-of-autophagy-related-genes
#15
Dong Chen, Junyi Chen, Yihong Guo, Yining Li
The effects of cinobufacini on apoptosis of human bladder cancer T24 cells and the expression of autophagy-related genes and proteins were studied. The human bladder cancer T24 cells were selected, and the inhibitory effect of cinobufacini on the proliferation of human bladder cancer cells was detected by cell viability assay. Flow cytometry and Hoechst staining were used to detect the changes in the apoptosis of bladder cancer cells after being treated with cinobufacini; the changes in the expression levels of human bladder cancer cell apoptosis-related genes and proteins, cleaved caspase-3, Bax, B-cell lymphoma-2 (Bcl-2) and autophagy-related genes and proteins, p62, light chain 3 (LC3) and autophagy-related protein 7 (Atg7) after treatment with cinobufacini were detected by western blot analysis and reverse transcription polymerase chain reaction (RT-PCR)...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29723931/photosensitizing-antihypertensive-drug-use-and-risk-of-cutaneous-squamous-cell-carcinoma
#16
K A Su, L A Habel, N S Achacoso, G D Friedman, M M Asgari
BACKGROUND: Many antihypertensive drugs (ADs) are photosensitizing, heightening reactivity of the skin to sunlight. Photosensitizing ADs have been associated with lip cancer, but whether they impact cutaneous squamous cell carcinoma (cSCC) risk is unknown. OBJECTIVES: To examine the association between AD use and cSCC risk among a cohort of non-Hispanic whites with hypertension enrolled in a comprehensive integrated healthcare delivery system in northern California (n=28,357)...
May 3, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29717388/dimerization-of-at-2-and-mas-receptors-in-control-of-blood-pressure
#17
REVIEW
Sanket Patel, Tahir Hussain
PURPOSE OF REVIEW: Angiotensin type 2 receptor (AT2 R) and receptor Mas (MasR) are part of the "protective arm" of the renin angiotensin system. Gene and pharmacological manipulation studies reveal that AT2 R and MasR are involved in natriuretic, vasodilatory, and anti-inflammatory responses and in lowering blood pressure in various animal models under normal and pathological conditions such as salt-sensitive hypertension, obesity, and diabetes. The scope of this review is to discuss co-localization and heterodimerization as potential molecular mechanisms of AT2 R- and MasR-mediated functions including antihypertensive activities...
May 1, 2018: Current Hypertension Reports
https://www.readbyqxmd.com/read/29706566/fgf21-prevents-angiotensin-ii-induced-hypertension-and-vascular-dysfunction-by-activation-of-ace2-angiotensin-1-7-axis-in-mice
#18
Xuebo Pan, Yihui Shao, Fan Wu, Yuan Wang, Rongrong Xiong, Jujia Zheng, Haishan Tian, Baile Wang, Yanfang Wang, Yi Zhang, Zongsheng Han, Aijuan Qu, Haixia Xu, Aihua Lu, Tianxin Yang, Xiaokun Li, Aimin Xu, Jie Du, Zhuofeng Lin
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage...
April 24, 2018: Cell Metabolism
https://www.readbyqxmd.com/read/29702500/future-pharmacological-therapy-in-hypertension
#19
Merrill H Stewart, Carl J Lavie, Hector O Ventura
PURPOSE OF REVIEW: Hypertension (HTN) is a widespread and growing disease, with medication intolerance and side-effect present among many. To address these obstacles novel pharmacotherapy is an active area of drug development. This review seeks to explore future drug therapy for HTN in the preclinical and clinical arenas. RECENT FINDINGS: The future of pharmacological therapy in HTN consists of revisiting old pathways to find new targets and exploring wholly new approaches to provide additional avenues of treatment...
April 26, 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29699885/impact-of-a-primary-care-ckd-registry-in-a-us-public-safety-net-health-care-delivery-system-a-pragmatic-randomized-trial
#20
Delphine S Tuot, Charles E McCulloch, Alexandra Velasquez, Dean Schillinger, Chi-Yuan Hsu, Margaret Handley, Neil R Powe
BACKGROUND: Many individuals with chronic kidney disease (CKD) do not receive guideline-concordant care. We examined the impact of a team-based primary care CKD registry on clinical measures and processes of care among patients with CKD cared for in a public safety-net health care delivery system. STUDY DESIGN: Pragmatic trial of a CKD registry versus a usual-care registry for 1 year. SETTING & PARTICIPANTS: Primary care providers (PCPs) and their patients with CKD in a safety-net primary care setting in San Francisco...
April 23, 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
keyword
keyword
117682
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"